Table 3

Construct validity as assessed by change in scores from baseline to week 6 in adalimumab group compared with placebo group

	Adalimumab		Placebo		Difference in change score from baseline to week 6, P value
	Baseline (n=25)	Change at week 6 (n=24)	Baseline (n=24)	Change at week 6 (n=23)	Difference in change score from baseline to week 6, P value
CANDEN spine total inflammation score	10.2 (13)	−5.7 (9.2)	7.3 (10)	−0.8 (3.0)	0.03
Vertebral body subscore	9.5 (12)	−5.2 (8.3)	6.9 (9.9)	−0.9 (2.6)	0.03
Anterior corner subscore	3.9 (5.6)	−2.0 (3.8)	3.3 (4.3)	−0.3 (1.2)	0.21
Posterior corner subscore	1.5 (2.6)	−0.9 (1.8)	1.3 (2.4)	0.0 (0.4)	0.01
Non-corner subscore	1.5 (3.2)	−0.3 (0.8)	0.9 (2.4)	−0.2 (0.8)	0.21
Lateral corner subscore	2.5 (3.8)	−1.9 (3.2)	1.5 (2.5)	−0.4 (1.8)	0.03
Posterior elements subscore	0.7 (2.3)	−0.5 (1.7)	0.4 (0.8)	0.1 (0.6)	0.16
SPARCC MRI spine index (23-DVU)	11.0 (14)	−6.3 (10)	8.7 (13)	−1.5 (3.7)	0.05
CANDEN spine erosion score	0.7 (1.7)	0.0 (0.2)	0.6 (0.9)	0.0 (0.1)	0.58
Fat Spondyloarthritis Spine Score	7.8 (11)	0.7 (2.7)	3.2 (5.5)	0.1 (0.6)	0.35
CANDEN new bone formation score	9.3 (26)	0.2 (0.6)	5.7 (12)	0.3 (0.9)	0.92
mSASSS	8.0 (15)	NA	6.3 (12)	NA	NA
BASDAI	6.3 (1.2)	−2.4 (2.2)	6.4 (1.5)	−0.6 (1.8)	0.01

All values as mean (SD). Significance tests for difference in change scores at week 6 between groups were calculated by Mann-Whitney U tests with continuity correction. Two patients in the adalimumab group had missing BASDAI values at week 6 and were excluded from the BASDAI results. MRI scores were the average of the two readers. Lateral corner subscore is the sum of antero-lateral and postero-lateral lesion scores.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CANDEN, Canada-Denmark; DVU, discovertebral unit; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NA, not available; PE, posterior elements; SPARCC, Spondyloarthritis Research Consortium of Canada.